*Average weight loss based on 68 and 72 week clinical trials studying semaglutide (2.4 mg) and tirzepatide (10-15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related health condition, the average weight loss was 15% and 20% respectively
[PubMed] [Google Scholar] Gjurasin M, Miklic P, Zupancic B, et al
Efficacy ratings per the CGIS reflected a combination of perceived improvement relative to side effects, the latter of which was largely based on parent anecdotal report and the familys adherence to study regimens
Because of its reparative properties, treatment with BPC157 offers advantages over the use of steroids
The potential protective effects of calcitonin involved in coordinating chondrocyte response, extracellular matrix, and subchondral trabecular bone in experimental osteoarthritis